Brief: Quince Therapeutics Board Approves Termination Of License Agreement By And Between Co, Purdue Research Foundation

IRulya Therapeutics

22/12/2023 21:32

Dec 22 (Reuters) - Quince Therapeutics Inc  QNCX.O :
    * QUINCE THERAPEUTICS - ON DECEMBER 22, BOARD APPROVED
CERTAIN
MUTUAL TERMINATION OF LICENSE AGREEMENT BY AND BETWEEN CO,
PURDUE RESEARCH FOUNDATION
    * QUINCE THERAPEUTICS- UNDER THE TERMINATION AGREEMENT, THE
LICENSE AGREEMENT IS TERMINATED EFFECTIVE AS OF OCTOBER 31, 2023
    * QUINCE THERAPEUTICS- AGREED TO REIMBURSE PRF FOR CERTAIN
FEES,
COSTS INCURRED REGARDING PROSECUTION OF LICENSED PATENTS PRIOR
TO TERMINATION

Further company coverage:  QNCX.O 

 ((Reuters.Briefs@thomsonreuters.com;))